Media
[News] Hua Medicine Will Present Research Results at the 2026 American Diabetes Association (ADA) Scientific Sessions
May 20, 2026 - Shanghai, China
Hua Medicine ("the Company", stock code: 2552.HK) announced today that it will present a series of research results of dorzagliatin, the Company's global first-in-class glucokinase activator (GKA), at the 86th American Diabetes Association (ADA) Scientific Sessions.
Through oral presentations and poster exhibitions, the Company will comprehensively present findings from combination therapy potential, large-scale post-marketing real-world studies, and AI-powered applications in diabetes diagnosis, management and treatment, further consolidating the global leadership of its metabolic homeostasis technology platform and expanding new frontiers in the treatment of broad metabolic disorders.
At this year's ADA Scientific Sessions, Hua Medicine will present the combination therapy study of dorzagliatin and oral GLP-1 receptor agonist orforglipron as an oral presentation, and will showcase the synergistic effects of dorzagliatin in combination with THRβ agonists and PanPPAR agonists in the form of posters. These findings are expected to deliver novel therapeutic inspiration for a broad range of metabolic disorders including obesity and MASLD.
Hua Medicine will also exhibit key data from large-scale post-marketing real-world studies of dorzagliatin via posters, covering more than 2,000 patients with type 2 diabetes. It will further provide clinical evidence for its application in complex baseline patients with wider ranges of age, BMI and disease course, as well as those taking more combined medications. This aims to verify that the observed efficacy and safety profiles are consistent with its established properties, and accumulate further real-world evidence for its extensive clinical application.
In addition, Hua Medicine will present a series of research achievements, including: a glucokinase knowledge base and LLM empowered interactive education platform --- GK Charger; the development of preliminary predictive models for dorzagliatin treatment response and diabetes remission; and innovative applications of AI in precision diabetes care such as patient stratification and MODY2 treatment, promoting the development of diabetes diagnosis and management toward personalization and intelligence.
As the world's largest and most important academic event in diabetes, the 2026 ADA Scientific Sessions will be held from June 5 to 8 in New Orleans, USA, gathering top global experts and scholars to discuss frontier breakthroughs in diabetes and metabolic diseases. Since 2014, Hua Medicine and its clinical experts have consistently presented innovative and groundbreaking results of basic and clinical research in the field of metabolic disease at the ADA Annual Scientific Sessions. This year, the Company will demonstrate the global academic influence of China's innovative drugs with an even richer research portfolio.
Hua Medicine Schedule
|
Oral Presentation: 1322-OR |
|
|
Title: |
Synergistic Effects of Dorzagliatin and Orforglipron on Glycemic Control and Adiposity in DIO Mice |
|
Presentation Time: |
Central Time 13:30-15:00, June 8 |
|
Session: |
GLP-1 and What Else? Preclinical Obesity Studies |
|
Venue: |
343 (Level 3) |
|
Poster Code: 1828-P |
|
|
Title: |
Development of Preliminary Predictive Models for Dorzagliatin Treatment Response and Diabetes Remission in Type 2 Diabetes: A Focus on Personalized Medicine |
|
Presentation Time: |
Central Time 12:30-13:30, June 7 |
|
Session: |
Sunday General Poster Session |
|
Venue: |
Poster Hall (Halls D-E) |
|
Poster Code: 1799-P |
|
|
Title: |
Safety and Efficacy of Dorzagliatin in Patients with Type 2 Diabetes under Real-World Clinical Practice: Preliminary Results from a Large-Scale Post-marketing Study |
|
Presentation Time: |
Central Time 12:30-13:30, June 7 |
|
Session: |
General Poster Session |
|
Venue: |
Poster Hall (Halls D-E) |
|
Poster Code: 2479-P |
|
|
Title: |
Synergistic Metabolic and Hepatic Benefits of Dorzagliatin and Resmetirom in MASLD Mice |
|
On-site Display Time: |
Central Time 12:30-13:30, June 7 |
|
Session: |
Sunday General Poster Session |
|
Venue: |
Poster Hall (Halls D-E) |
|
Poster Code: 1479-P |
|
|
Title: |
GK Charger: An LLM-Empowered Knowledge Platform for Interactive Education in Glucokinase-Based Diabetes Therapy |
|
On-site Display Time: |
Central Time 12:30-13:30, June 8 |
|
Session: |
Monday General Poster Session |
|
Venue: |
Poster Hall (Halls D-E) |
|
Poster Code: 1774-P |
|
|
Title: |
Structural Mechanisms and AI-Driven Prediction of Glucokinase Variants: Advancing Precision Medicine in MODY2 |
|
On-site Display Time: |
Central Time 12:30-13:30, June 7 |
|
Session: |
General Poster Session |
|
Venue: |
Poster Hall (Halls D-E) |
|
Poster Code: 1912-P |
|
|
Title: |
A Novel ATP-Independent Enzymatic Cycling System for Glucose Removal Enables Accurate Quantification of 1,5-anhydroglucitol |
|
On-site Display Time: |
Central Time 12:30-13:30, June 6 |
|
Session: |
General Poster Session |
|
Venue: |
Poster Hall (Halls D-E) |
|
Poster Code: 3049-LB |
|
|
Title: |
Synergistic Effects of Dorzagliatin and Chiglitazar on Metabolic in DIO Mice with MASLD |
|
On-site Display Time: |
Central Time 12:30-13:30, June 7 |
|
Session: |
Late Breaking Abstract Session |
|
Venue: |
Poster Hall (Halls D-E) |
|
Poster Code: 2874-LB |
|
|
Title: |
Dorzagliatin improves glycemic control in type 2 diabetes patients with different time in range (TIR): A subgroup analysis of 6-month interim results from a prospective real-world study |
|
On-site Display Time: |
Central Time 12:30-13:30, June 7 |
|
Session: |
Late Breaking Abstract Session |
|
Venue: |
Poster Hall (Halls D-E) |
About Hua Medicine
Hua Medicine (The "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
